psilocybin – Page 9

The phenomenology of psilocybin’s experience mediates subsequent persistent psychological effects independently of sex, previous experience, or setting

mycolabadmin

A research study examined how psilocybin experiences affect long-term mental health and well-being in healthy volunteers. Participants received two doses of psilocybin in controlled medical settings while undergoing brain imaging. The study found that psilocybin consistently produced positive, lasting improvements in mood, well-being, and spiritual outlook, regardless of whether people had used psychedelics before, their sex, or the specific imaging setting used.

Deconstructing Psychedelic Phenomenology: A Thematic Analysis of Discrete Phases of the Psychedelic Experience

mycolabadmin

This study examined how people describe their experiences with psychedelic drugs by analyzing personal accounts shared online. Researchers found that experiences naturally fall into three phases: preparation (where knowledge and intentions matter), the actual experience (where sensory changes, mindset, and environment shape what happens), and afterward (where lasting behavioral and attitude changes occur). The study highlights how music, nature, supportive people, and clear intentions can help guide psychedelic experiences toward positive, meaningful outcomes.

Attitudes toward psychedelics and psychedelic-assisted therapy among potential mental health service users and the general population in Australia

mycolabadmin

This Australian study surveyed over 500 people about their views on psychedelics like psilocybin and MDMA for treating mental health conditions. Most people supported medical legalization of these substances, though many had safety concerns. Those with mental illness, those with prior psychedelic experience, and those with better knowledge of psychedelics were most supportive of their therapeutic use.

Chemical Composition and Biological Activities of Psilocybe Mushrooms: Gaps and Perspectives

mycolabadmin

This comprehensive review examined what we know about Psilocybe mushrooms, which are known for their mind-altering effects due to compounds called psilocybin and psilocin. The study found that while these mushrooms show promise for treating depression and anxiety, most research has focused only on their psychoactive properties. The review identified over 30 chemical compounds in these mushrooms and noted that some species show potential antimicrobial and antioxidant properties. The authors emphasize that much more research is needed to explore other potential health benefits and to understand exactly how individual compounds work in the body.

Striking long-term beneficial effects of single dose psilocybin and psychedelic mushroom extract in the SAPAP3 rodent model of OCD-like excessive self-grooming

mycolabadmin

Researchers tested whether psilocybin (the active compound in magic mushrooms) could treat obsessive-compulsive disorder using genetically modified mice that exhibit excessive grooming similar to OCD in humans. A single dose of psilocybin or psychedelic mushroom extract significantly reduced the excessive grooming behavior and anxiety in these mice, with benefits lasting up to six weeks. These findings suggest psilocybin may be a promising new treatment for OCD in humans, offering longer-lasting effects from a single dose compared to current medications.

Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings

mycolabadmin

This clinical trial is investigating whether psilocybin (a psychoactive compound found in certain mushrooms) combined with supportive counseling can help people with treatment-resistant obsessive-compulsive disorder. Researchers will give participants two doses of psilocybin while providing non-directive psychological support to help them process their experiences. The study aims to determine whether this approach is safe, tolerable, and effective at reducing OCD symptoms, and to understand the psychological mechanisms that might explain how it works.

Psilocybin: Systematic review of its use in the treatment of depression

mycolabadmin

Researchers reviewed scientific studies on psilocybin, a psychedelic compound found in certain mushrooms, as a treatment for depression. The studies showed that psilocybin significantly reduced depressive symptoms faster than standard treatments, with minimal side effects. This suggests psilocybin could be a promising new option for people with depression who haven’t benefited from traditional medications.

Genetic regulation of l-tryptophan metabolism in Psilocybe mexicana supports psilocybin biosynthesis

mycolabadmin

Researchers studied how magic mushrooms (Psilocybe mexicana) regulate their chemistry to produce psilocybin, the psychoactive compound. They found that when mushrooms start fruiting, they turn on genes that make tryptophan (an amino acid building block) and turn off genes that break it down, directing all the tryptophan toward psilocybin production. This coordinated genetic control ensures the mushroom has enough of this key ingredient. This knowledge could help grow these mushrooms in labs for legitimate medical research into treating depression.

Mycelium Growth and Development of Psilocybe spp. Mother Cultures on Agar-Based Media

mycolabadmin

This research examines how different growing media affect four types of psilocybin mushrooms. The study found that malt extract agar worked best for some mushroom types while potato-based media worked better for others. Commercial powdered potato media performed poorly, especially for one sensitive strain. These findings help optimize mushroom cultivation for therapeutic and commercial purposes.

Exploring Psilocybe spp. mycelium and fruiting body chemistry for potential therapeutic compounds

mycolabadmin

This study analyzed the chemical composition of ‘magic mushrooms’ (Psilocybe) at different growth stages—liquid cultures, grain cultures, and mature fruiting bodies. Using advanced laboratory techniques, researchers found that fruiting bodies contain the highest levels of psilocybin (the psychoactive compound), while mycelium contains unique beneficial compounds like alpha-glycerylphosphorylcholine that may have therapeutic value without strong psychedelic effects. The findings suggest that Psilocybe mycelium could be developed as a non-intoxicating health supplement with potential therapeutic applications.

Research Keyword: psilocybin